NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc.’s (NASDAQ: CLDA) PGxHealthTM division announced today that beginning October 22, 2007 its FAMILION family of genetic tests for cardiac channelopathies will include a test for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) mutations. Added in response to requests from doctors using the FAMILION Long QT Syndrome (LQTS) tests, the FAMILION CPVT test is designed to reveal mutations of the cardiac ryanodine receptor gene (RYR2).
